These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 27164191)

  • 1. Association of androgen metabolism gene polymorphisms with prostate cancer risk and androgen concentrations: Results from the Prostate Cancer Prevention Trial.
    Price DK; Chau CH; Till C; Goodman PJ; Leach RJ; Johnson-Pais TL; Hsing AW; Hoque A; Parnes HL; Schenk JM; Tangen CM; Thompson IM; Reichardt JK; Figg WD
    Cancer; 2016 Aug; 122(15):2332-40. PubMed ID: 27164191
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of genetic variations in the androgen and estrogen metabolic pathways as risk factors for sporadic and familial prostate cancer.
    Cunningham JM; Hebbring SJ; McDonnell SK; Cicek MS; Christensen GB; Wang L; Jacobsen SJ; Cerhan JR; Blute ML; Schaid DJ; Thibodeau SN
    Cancer Epidemiol Biomarkers Prev; 2007 May; 16(5):969-78. PubMed ID: 17507624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The association between polymorphisms in the CYP17 and 5alpha-reductase (SRD5A2) genes and serum androgen concentrations in men.
    Allen NE; Forrest MS; Key TJ
    Cancer Epidemiol Biomarkers Prev; 2001 Mar; 10(3):185-9. PubMed ID: 11303586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Importance of 5α-reductase gene polymorphisms on circulating and intraprostatic androgens in prostate cancer.
    Lévesque É; Laverdière I; Lacombe L; Caron P; Rouleau M; Turcotte V; Têtu B; Fradet Y; Guillemette C
    Clin Cancer Res; 2014 Feb; 20(3):576-84. PubMed ID: 24277450
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic variations in genes involved in testosterone metabolism are associated with prostate cancer progression: A Spanish multicenter study.
    Henríquez-Hernández LA; Valenciano A; Foro-Arnalot P; Álvarez-Cubero MJ; Cozar JM; Suárez-Novo JF; Castells-Esteve M; Fernández-Gonzalo P; De-Paula-Carranza B; Ferrer M; Guedea F; Sancho-Pardo G; Craven-Bartle J; Ortiz-Gordillo MJ; Cabrera-Roldán P; Rodríguez-Melcón JI; Herrera-Ramos E; Rodríguez-Gallego C; Lara PC
    Urol Oncol; 2015 Jul; 33(7):331.e1-7. PubMed ID: 25960412
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between two polymorphisms in the SRD5A2 gene and serum androgen concentrations in British men.
    Allen NE; Reichardt JK; Nguyen H; Key TJ
    Cancer Epidemiol Biomarkers Prev; 2003 Jun; 12(6):578-81. PubMed ID: 12815006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SRD5A1 and SRD5A2 are associated with treatment for benign prostatic hyperplasia with the combination of 5α-reductase inhibitors and α-adrenergic receptor antagonists.
    Gu X; Na R; Huang T; Wang L; Tao S; Tian L; Chen Z; Jiao Y; Kang J; Zheng S; Xu J; Sun J; Qi J
    J Urol; 2013 Aug; 190(2):615-9. PubMed ID: 23499746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Associations between polymorphisms in genes related to estrogen metabolism and function and prostate cancer risk: results from the Prostate Cancer Prevention Trial.
    Tang L; Platek ME; Yao S; Till C; Goodman PJ; Tangen CM; Wu Y; Platz EA; Neuhouser ML; Stanczyk FZ; Reichardt JKV; Santella RM; Hsing A; Figg WD; Lippman SM; Thompson IM; Ambrosone CB
    Carcinogenesis; 2018 Feb; 39(2):125-133. PubMed ID: 29228205
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of the polymorphisms of genes involved in androgen metabolism and signaling pathways with familial prostate cancer risk in a Japanese population.
    Okugi H; Nakazato H; Matsui H; Ohtake N; Nakata S; Suzuki K
    Cancer Detect Prev; 2006; 30(3):262-8. PubMed ID: 16859836
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Case-only Methods Identified Genetic Loci Predicting a Subgroup of Men with Reduced Risk of High-grade Prostate Cancer by Finasteride.
    Dai JY; LeBlanc M; Goodman PJ; Lucia MS; Thompson IM; Tangen CM
    Cancer Prev Res (Phila); 2019 Feb; 12(2):113-120. PubMed ID: 30538099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The interaction of CYP3A5 polymorphisms along the androgen metabolism pathway in prostate cancer.
    Vaarala MH; Mattila H; Ohtonen P; Tammela TL; Paavonen TK; Schleutker J
    Int J Cancer; 2008 Jun; 122(11):2511-6. PubMed ID: 18306354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular Analysis of the SRD5A1 and SRD5A2 Genes in Patients with Benign Prostatic Hyperplasia with Regard to Metabolic Parameters and Selected Hormone Levels.
    Rył A; Rotter I; Grzywacz A; Małecka I; Skonieczna-Żydecka K; Grzesiak K; Słojewski M; Szylińska A; Sipak-Szmigiel O; Piasecka M; Walczakiewicz K; Laszczyńska M
    Int J Environ Res Public Health; 2017 Oct; 14(11):. PubMed ID: 29084161
    [No Abstract]   [Full Text] [Related]  

  • 13. Prostate carcinoma risk and allelic variants of genes involved in androgen biosynthesis and metabolism pathways.
    Latil AG; Azzouzi R; Cancel GS; Guillaume EC; Cochan-Priollet B; Berthon PL; Cussenot O
    Cancer; 2001 Sep; 92(5):1130-7. PubMed ID: 11571725
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vitamin D Pathway and Other Related Polymorphisms and Risk of Prostate Cancer: Results from the Prostate Cancer Prevention Trial.
    Torkko K; Till C; Tangen CM; Goodman PJ; Song X; Schenk JM; Lucia MS; Peters U; van Bokhoven A; Thompson IM; Neuhouser ML
    Cancer Prev Res (Phila); 2020 Jun; 13(6):521-530. PubMed ID: 32102946
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 5alpha-reductase 2 polymorphisms as risk factors in prostate cancer.
    Söderström T; Wadelius M; Andersson SO; Johansson JE; Johansson S; Granath F; Rane A
    Pharmacogenetics; 2002 Jun; 12(4):307-12. PubMed ID: 12042668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The association of 5-alpha reductase type 2 (SRD5A2) gene polymorphisms with prostate cancer in a Korean population.
    Choi SY; Kim HJ; Cheong HS; Myung SC
    Korean J Urol; 2015 Jan; 56(1):19-30. PubMed ID: 25598933
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polymorphic markers in the SRD5A2 gene and prostate cancer risk: a population-based case-control study.
    Hsing AW; Chen C; Chokkalingam AP; Gao YT; Dightman DA; Nguyen HT; Deng J; Cheng J; Sesterhenn IA; Mostofi FK; Stanczyk FZ; Reichardt JK
    Cancer Epidemiol Biomarkers Prev; 2001 Oct; 10(10):1077-82. PubMed ID: 11588134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic polymorphisms in the androgen metabolism pathway and risk of prostate cancer in low incidence Malaysian ethnic groups.
    Poniah P; Mohamed Z; Apalasamy YD; Mohd Zain S; Kuppusamy S; Razack AH
    Int J Clin Exp Med; 2015; 8(10):19232-40. PubMed ID: 26770559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Germ-line genetic variation in the key androgen-regulating genes androgen receptor, cytochrome P450, and steroid-5-alpha-reductase type 2 is important for prostate cancer development.
    Lindström S; Wiklund F; Adami HO; Bälter KA; Adolfsson J; Grönberg H
    Cancer Res; 2006 Nov; 66(22):11077-83. PubMed ID: 17108148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate cancer risk and polymorphism in 17 hydroxylase (CYP17) and steroid reductase (SRD5A2).
    Lunn RM; Bell DA; Mohler JL; Taylor JA
    Carcinogenesis; 1999 Sep; 20(9):1727-31. PubMed ID: 10469617
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.